487 related articles for article (PubMed ID: 37542343)
21. Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.
Diao Z; Han Y; Zhang R; Li J
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188363. PubMed ID: 32275933
[TBL] [Abstract][Full Text] [Related]
22. Liquid biopsy in CNS tumors: Current status & future perspectives.
Husain N; Husain A; Mishra S; Srivastava P
Indian J Pathol Microbiol; 2022 May; 65(Supplement):S111-S121. PubMed ID: 35562141
[TBL] [Abstract][Full Text] [Related]
23. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
24. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges.
García-Pardo M; Makarem M; Li JJN; Kelly D; Leighl NB
Br J Cancer; 2022 Sep; 127(4):592-602. PubMed ID: 35347327
[TBL] [Abstract][Full Text] [Related]
25. Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer.
Pellini B; Szymanski J; Chin RI; Jones PA; Chaudhuri AA
Thorac Surg Clin; 2020 May; 30(2):165-177. PubMed ID: 32327175
[TBL] [Abstract][Full Text] [Related]
26. The role of circulating free DNA in the management of NSCLC.
Esposito Abate R; Pasquale R; Fenizia F; Rachiglio AM; Roma C; Bergantino F; Forgione L; Lambiase M; Sacco A; Piccirillo MC; Morabito A; Normanno N
Expert Rev Anticancer Ther; 2019 Jan; 19(1):19-28. PubMed ID: 30462523
[TBL] [Abstract][Full Text] [Related]
27. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.
Scilla KA; Rolfo C
Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467
[TBL] [Abstract][Full Text] [Related]
28. Dynamic Treatment Stratification Using ctDNA.
Vidal J; Taus A; Montagut C
Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
[TBL] [Abstract][Full Text] [Related]
29. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA.
Onidani K; Shoji H; Kakizaki T; Yoshimoto S; Okaya S; Miura N; Sekikawa S; Furuta K; Lim CT; Shibahara T; Boku N; Kato K; Honda K
Cancer Sci; 2019 Aug; 110(8):2590-2599. PubMed ID: 31169336
[TBL] [Abstract][Full Text] [Related]
30. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
[TBL] [Abstract][Full Text] [Related]
31. The evolving role of liquid biopsy in lung cancer.
Malapelle U; Pisapia P; Pepe F; Russo G; Buono M; Russo A; Gomez J; Khorshid O; Mack PC; Rolfo C; Troncone G
Lung Cancer; 2022 Oct; 172():53-64. PubMed ID: 35998482
[TBL] [Abstract][Full Text] [Related]
32. Liquid biopsy in gastric cancer: predictive and prognostic biomarkers.
Zhang Z; Wu H; Chong W; Shang L; Jing C; Li L
Cell Death Dis; 2022 Oct; 13(10):903. PubMed ID: 36302755
[TBL] [Abstract][Full Text] [Related]
33. Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer.
Al-Obeidi E; Riess JW; Malapelle U; Rolfo C; Gandara DR
Hematol Oncol Clin North Am; 2023 Jun; 37(3):475-487. PubMed ID: 37024388
[TBL] [Abstract][Full Text] [Related]
34. Liquid Biopsy and Lung Cancer.
Pisapia P; Malapelle U; Troncone G
Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
[TBL] [Abstract][Full Text] [Related]
35. Liquid Biopsy of Non-Plasma Body Fluids in Non-Small Cell Lung Cancer: Look Closer to the Tumor!
Durin L; Pradines A; Basset C; Ulrich B; Keller L; Dongay V; Favre G; Mazieres J; Guibert N
Cells; 2020 Nov; 9(11):. PubMed ID: 33207539
[TBL] [Abstract][Full Text] [Related]
36. Circulating tumor DNA: current challenges for clinical utility.
Dang DK; Park BH
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703177
[TBL] [Abstract][Full Text] [Related]
37. Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring.
Martins I; Ribeiro IP; Jorge J; Gonçalves AC; Sarmento-Ribeiro AB; Melo JB; Carreira IM
Genes (Basel); 2021 Feb; 12(3):. PubMed ID: 33673461
[TBL] [Abstract][Full Text] [Related]
38. Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis.
Benesova L; Ptackova R; Halkova T; Semyakina A; Svaton M; Fiala O; Pesek M; Minarik M
Pathol Oncol Res; 2022; 28():1610308. PubMed ID: 35837614
[No Abstract] [Full Text] [Related]
39. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
Nakamura Y; Yoshino T
Oncologist; 2018 Nov; 23(11):1310-1318. PubMed ID: 29700206
[TBL] [Abstract][Full Text] [Related]
40. Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?
Yang M; Forbes ME; Bitting RL; O'Neill SS; Chou PC; Topaloglu U; Miller LD; Hawkins GA; Grant SC; DeYoung BR; Petty WJ; Chen K; Pasche BC; Zhang W
Ann Oncol; 2018 Feb; 29(2):311-323. PubMed ID: 29216340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
